Actinium Pharmaceuticals Announces Presentation for Actimab-A, a Novel Targeted Immunotherapy for Acute Myeloid Leukemia at the 8th Annual Hematologic Malignancies 2012 Conference Results supporting further development of Actimab-A for Elderly AML
NEW YORK, Oct. 10, 2012 /PRNewswire/ -- Actinium Pharmaceuticals, Inc., (API), a privately held biopharmaceutical company that develops innovative targeted radio-immunotherapeutics, announced the presentation of a scientific poster summarizing the results for a Phase I study of Actimab-A, its antibody directed alpha emitter drug candidate for the front line treatment of acute myeloid leukemia in older patients. Actimab-A was evaluated in a Phase I dose escalating trial at Memorial Sloan Kettering Cancer Center (MSKCC). The poster entitled, "Phase I Trial of the Targeted Alpha-Particle Nano-Generator Actinium-225 (225Ac)-Lintuzumab in Acute Myeloid Leukemia (AML)" will be presented at the 8th Annual Hematologic Malignancies 2012 Conference to be held from October 10-14, 2012 at the Hilton Americas Houston in Houston, TX.
The poster summarizes key findings from the Phase I trial conducted at MSKCC with Dr. Joseph Jurcic as the Primary Investigator. The goal of the trial was to determine the maximum tolerated dose (MTD), toxicity, pharmacokinetics, and antileukemic activity of 225Ac-lintuzumab. It was a first-in-man, Phase I, dose-escalation trial.
This is the first study to show that therapy with an antibody targeted alpha particle generator is feasible in humans. The study has demonstrated that Actimab-A (Lintuzumab-Ac-225) has significant antileukemic activity across all dose levels and the drug candidate is now being further investigated in a multicenter Phase I/II trial in combination with low-dose cytarabine for older AML patients.
Dr. Jurcic will present these findings at the Hematologic Malignancies 2012 Conference at 6:30 PM on Wednesday, October 10, 2012.
"We are pleased that these findings confirm the utility of Actimab-A in the treatment of elderly acute myeloid leukemia," said Jack Talley, CEO of Actinium. "AML is one of the most difficult to treat diseases, especially in older patients and we are looking forward to providing a front line treatment for the majority of older patients who cannot tolerate current intensive chemotherapy regimens. As we continue to announce key milestones we are moving quickly towards a Phase II trial which is targeted to start early in 2013."
About Actinium 225
Actinium-225 decays by giving off high-energy alpha particles, which kill cancer cells. When actinium decays, it produces a series of daughter atoms, each of which gives off its own alpha particle, increasing the chances that the cancer cell will be destroyed. The technology was first developed by Dr. David Scheinberg at Memorial Sloan Kettering Cancer Center.
About Lintuzumab (HuM195)
Lintuzumab is a monoclonal antibody that targets CD33, found on myeloid leukemia cells. It is the humanized version of M195, the antibody initially developed by Dr. David Scheinberg of Memorial Sloan Kettering Cancer Center.
About Acute Myeloid Leukemia
Acute Myeloid Leukemia is the most difficult to treat form of leukemia. The majority of patients are older than 60 and most of them do not qualify for the commonly used chemotherapy regimens and their median survival following diagnosis is about two months without treatment.
About Actinium Pharmaceuticals
Actinium Pharmaceuticals, Inc. is a New York, New York based biopharmaceutical company that develops innovative immunotherapeutics based on its proprietary platform for the therapeutic utilization radiopharmaceuticals in association with monoclonal antibodies.
For more information:
Visit our web site www.actiniumpharmaceuticals.com or contact:
Jack Talley, CEO
Actinium Pharmaceuticals Inc.
Tel: (646) 459-4201
Forward-Looking Statement for Actinium Pharmaceuticals, Inc.
This news release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Actinium Pharmaceuticals undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.
SOURCE Actinium Pharmaceuticals, Inc.